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1. Intoduction 
In recent years with new anticancer therapies, many patients can have a long life 
expectancy. According to recently published data there are at present more than 12 million 
cancer survivors in the United States and in Europe (CDC, 2011; Coleman et al., 2003). These 
patients are prone to higher risk of cardiovascular death than the risk of tumor recurrence, 
particularly in childhood cancer survivors in which the cardiac mortality rate is sevenfold 
higher (Scully et al., 2007). However, cardiac toxicity remains an important side effect of 
anticancer therapies, leading to increased mortality due to mainly heart failure, but also 
myocardial ischemia, arrhythmias, hypertension, thromboembolism. The time from early 
development of cardiac dysfunction to the modification or end of chemotherapy and 
beginning of heart failure therapy, is an important determinant of the extent of recovery. 
Using conventional strategies with serial measurement of left ventricular ejection fraction, 
the time from first asymptomatic cardiac changes to clinical onset of cardiac dysfunction 
with heart failure may be lost for preventive therapy. This underlines the need for a real-
time diagnosis of cardiac injury which represents the main goal for cardiologists and 
oncologists. 
According to the general consensus the definition of chemotherapy-related cardiotoxicity 
include decrease in left ventricular ejection fraction by more than 20% to a value >50%, a 
decrease of ejection fraction by more than 10% to a value <50%, or clinical manifestations 
with signs and symptoms of congestive heart failure. Some of the most accurate clinical 
criteria of preliminary diagnosis of cardiotoxicity are established by cardiac review and 
evaluation committee for trastuzumab clinical trials: (1) cardiomyopathy characterized by a 
decrease in cardiac left ventricular ejection fraction that was either global or more severe in 
the septum; (2) symptoms of congestive heart failure; (3) associated signs of congestive heart 
failure, including but not limited to S3 gallop, tachycardia, or both; (4) decline in left 
ventricular ejection fraction of at least 5% to less than 55% with accompanying signs or 
symptoms of congestive heart failure, or a decline in left ventricular ejection fraction of at 
least 10% to below 55% without accompanying signs or symptoms (Seidman et al., 2002). 
Any of the four criteria was sufficient to confirm a diagnosis of cardiac dysfunction.  
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The incidence of cardiotoxicity depends on treatment-related factors (type of drug, 
cumulative dose and schedule of administration, combination of potentially cardiotoxic 
drugs, or association with radiotherapy) or patient related factors (age, presence of 
cardiovascular risk factors or coexisting cardiac disease, and previous mediastinal 
irradiation) (Jurcut et al., 2008b). Heart injury usually is subclinical and may present as acute 
or early onset during therapy, chronic onset - within the first year, or late onset - 1 year or 
more after completion of treatment. The later form is usually irreversible, and its prediction 
is the most important challenge. 
The chemotherapeutic class of antracyclines is the most frequently implicated group and can 
cause an irreversible and sometimes fatal cardiomyopathy. The reported incidence of 
doxorubicin-induced cardiac dysfunction varies from 4%, at a cumulative dose of 500–550 
mg/m², to >36% in patients receiving 600 mg/m² or more (Singal et al., 1998). Moreover, in 
children, the estimated risk of antracycline-induced clinical heart failure increased with time to 
5.5% at 20 years after the start of therapy (van Dalen et al., 2006), and in patients treated with a 
cumulative antracycline dose of 300 mg/m² or more, the risk was even higher, almost 10%.  
For treatment of breast cancers with Her-2 amplification, doxorubicin is administered in 
combination with trastuzumab - a monoclonal antibody against the Her-2/neu receptor 
(also known as ErbB2 – epidermal growth factor receptor 2). The results from trials using 
combination of trastuzumab with anthracycline plus taxane-based adjuvant chemotherapy, 
suggest that approximately 5% of patients will develop objective evidence of cardiac 
dysfunction, 2% will develop symptomatic congestive heart failure, and 1% will develop 
severe heart failure (New York Heart Association class III or IV), (Slamon et al., 2001). Her-
2/neu receptors are superexpressed over the carcinoma cells in some kind of breast cancer 
but they are present at regulation of sarcomeric proteins which define the myocardial 
changes. However, in contrast to anthracyclines, cardiac failure due to trastuzumab 
administration appears, to a large extent, reversible. 
The therapeutic management of oncologic patients includes combinations of drugs, 
radiation therapy and surgery. Irradiation with a thoracic field (as used in lymphomas and 
breast or lung cancer) can damage the myocardium by injuring capillary endothelial cells, 
which leads to ischemia and then to myocardial cell death and fibrosis. These effects can be 
amplified by the use of other cardiotoxic chemotherapeutic agents.  
Although multiple mechanisms involved in doxorubicin cardiotoxicity have been studied 
there is no clinically proven treatment established for cardiotoxicity. Several approaches 
have been studied in order to reduce anticancer therapy-induced cardiotoxicity, from 
developing newer molecules (e.g., pegylated liposomal anthracyclines) (Batist et al., 2001), to 
the use of cardioprotective agents (dexrazoxane), and angiotensin converting enzyme 
inhibitors and ǃ-blockers (Shi et al., 2011). Vascular progenitor cells have been the focus of 
much attention in recent years, both from the point of view of their pathophysiological roles 
and their potential as therapeutic agents (Jevon et al., 2008) with the ability to differentiate 
into mature endothelial and vascular smooth muscle reportedly reside within a number of 
different tissues - bone marrow, spleen, cardiac muscle, skeletal muscle and adipose tissue. 
Progenitor cells remain quiescent, until mobilized in response to injury or disease. 
Mobilized, these progenitor cells enter the circulation and migrate to sites of damage, where 
they contribute to the remodeling process. The number of circulating endothelial progenitor 
cells inversely correlates with exposure to cardiovascular risk factors and numbers of animal 
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models and human studies have demonstrated therapeutic roles for endothelial progenitor 
cells, which can be enhanced by manipulating them to overexpress vasculo-protective genes 
(Jevon et al., 2008; Rodriquez-Losada et al., 2008).  
Until prophylaxis and therapeutic strategies for chemotherapy-related cardiotoxicity are 
established, close and accurate monitoring of cardiac function is recommended. Using a 
robust technique is important for early detection of cardiac dysfunction during anticancer 
therapy. Most international consensus guidelines for chemotherapy recommend serial 
measurement of left ventricular ejection fraction at the beginning of anticancer therapy, after 
administration of the half total cumulative dose and before every subsequent dose, as well 
as assessment at 3, 6 and 12 months after the end of treatment (Bovelli et al., 2010). Using 
this monitoring strategy the heart failure risk has been reduced to less than 3% in patients 
examined with equilibrium radionuclide angiocardiography (Mitani et al, 2003). However, 
subsequent reduction of ejection fraction by more than 10% or less than 50% as absolute 
value that was proposed as a criterion for suspending treatment (Schwartz et al., 1987, as 
cited by Dolci et al., 2008), is a relatively insensitively parameter for early cardiotoxicity 
detection. The possible explanation is that systolic dysfunction appears after a critical 
amount of myocardium has become damaged. Furthermore, the lack of reduction of ejection 
fraction does not exclude development of late cardiotoxicity (Aleman et al., 2007). 
Regardless of these limitations evaluation of ejection fraction has been used for monitoring 
left ventricular function in both clinical practice and clinical trials. Currently, there is no 
consensus statement on the method for efficient identification of patients at high risk for 
development of chemotherapy related cardiotoxicity.   
2. Biomarkers 
In recent years the biomarkers - enzymes, hormones, markers of cardiac stress and 
malfunction, as well as myocyte injury of inflammation, appear to have growing clinical 
importance and have become the subject of intense inquiry. A biomarker should fulfill three 
criteria to be useful clinically. First, accurate, repeated measurements must be available at a 
reasonable cost and with short times; second, the biomarker must provide additional 
information; and third, knowing the measured level should aid in medical decision making. 
The biomarkers that were proved to predict heart failure could be divided into six categories 
according to their origin or effects (inflammation, oxidative stress, extracellular matrix 
remodeling, neurohormones, myocyte injury, myocyte stress), and a seventh category of 
new biomarkers that have not yet been fully characterized (Braunwald et al., 2008). Heart 
failure, including in cardiotoxicity, appears to result from a complex interplay among 
genetic, neurohormonal, inflammatory, and biochemical changes acting on cardiac 
myocytes, the cardiac interstitium, or both.  
2.1 C-reactive protein 
C-reactive protein is an acute-phase reactant synthesized by hepatocytes in response to the 
proinflammatory cytokine interleukin-6. Increased levels of C-reactive protein correlate with 
the severity of heart failure and is an independent predictor of adverse outcomes in patients 
with acute or chronic heart failure (Anand et al., 2008). C-reactive protein has direct effects 
on the vascular endothelium by reducing nitric-oxide release and increasing endothelin-1 
production, as well as by inducing expression of endothelial adhesion molecules (Venugopal 
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et al., 2005). This marker may be useable in wide population because of the low-cost and 
high-sensitivity test was developed. In most studies C-reactive protein has been investigated 
as risk factor and prognostic variable in patients with various malignances. In patients with 
small cell lung cancer the baseline serum concentrations of the C-reactive protein were 
raised in most of patients and doubled during induction chemotherapy in chemosensitive 
patients but it did not in non-responders (Milroy et al., 1989).  In prospective study 
including ninety-five patients with breast cancer treated with dose-dense doxorubicin and 
cyclophosphamide, than weekly paclitaxel with trastuzumab and lapatinib, the levels of C-
reactive protein were measured every 2 weeks during chemotherapy then at months 6, 9 
and 18. During chemotherapy a detectable C-reactive protein was seen in 78% but did not 
correlate with ejection fraction declines (Morris et al., 2010). 
2.2 Tumor Necrosis Factor α (TNF-)  
Tumor necrosis factor ǂ (TNF-) and three interleukins (interleukins 1, 6, and 18) are 
considered to be proinflammatory cytokines and are produced by nucleated cells in the heart 
(Anker et al., 2004). According to the cytokine hypothesis of heart failure, proinflammatory 
cytokines are produced by the damaged myocardium, which is enhanced by stimulation of 
the sympathetic nervous system. Injured myocardium, as well as skeletal muscle, which is 
hypoperfused because of reduced cardiac output, activate monocytes to produce the same 
cytokines, which act on and further impair myocardial function as a result of apoptosis and 
necrosis. Interleukin-6 induces a hypertrophic response in myocytes, whereas TNF- causes 
left ventricular dilatation through activation of matrix metalloproteinases. Interleukin-6 and 
TNF- levels could be used to predict the future development of heart failure in 
asymptomatic elderly subjects (Lee et al., 2005) though blockade of TNF- has not resulted 
in clinical benefit in patients with heart failure (Anker et al., 2004). The increased levels of 
soluble members of the TNF-superfamily of apoptosis-related protein have been reported 
after a median follow-up of more than 6 years in patients after epirubicin-containing 
chemotherapy and chest wall irradiation for breast cancer especially after high-dose 
chemotherapy (Perik et al., 2006). To investigate if high TNF-protein levels are related to 
cardiac function, 40 breast cancer patients were examined following surgery, one month and 
one year after epirubicin-based chemotherapy. Significant but transient changes in soluble 
apoptotic protein levels were obsereved, particularly after high-dose chemotherapy but no 
relation was found between TNF-proteins and carditoxicity, assessed by electrocardiogram, 
conventional echocardiography and plasma natriuretic peptid.   
2.3 Markers of the oxidative stress 
Increased oxidative stress results from an imbalance between reactive oxygen species and 
endogenous antioxidant defense mechanisms. Since it is difficult to measure reactive oxygen 
species directly in humans, indirect markers of oxidative stress - plasma-oxidized low-
density lipoproteins, malondialdehyde and myeloperoxidase have been sought. In animal 
models administration of doxorubicin resulted in higher myeloperoxidase activity and lipid 
peroxidation (Fadillioglu et al., 2004). In twenty-two patients with non-Hodgkin’s 
lymphoma or Hodgkin’s disease, treated with doxorubicin-containing regimen the flow-
mediated dilation was monitored (Nagi et al., 2001). During the same time biochemical 
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markers were measured - the marker of lipid peroxidation (malondialdehyde), the amounts 
of the ratio of reduced to oxidized glutathione and the marker of free radical generating 
capacity of neutrophils (myeloperoxidase). No significant alterations were found in these 
biomarkers concentrations after doxorubicin bolus. 
2.4 Sympathetic nervous system and renin–angiotensin–aldosterone
 
system  
The sympathetic nervous system is activated in patients with heart failure and this lead to 
higher plasma levels of norepinephrine which was proved as an independent predictor of 
mortality (Cohn et al., 1984). Attention focused on big endothelin-1, secreted by vascular 
endothelial cells and then undergoes conversion into the active neurohormone endothelin-1, 
which is a powerful stimulant of vascular smooth-muscle contraction and proliferation and 
ventricular and vessel fibrosis. Besides the activation of sympathetic nervous system, the 
renin–angiotensin–aldosterone system becomes activated in patients with heart failure as 
well. In the Randomized Aldactone Evaluation Study (RALES) of patients with severe heart 
failure administration of the aldosterone blocker spironolactone was associated with a 
reduction of plasma procollagen type III and clinical benefit, but only in patients whose 
baseline levels of the procollagen were above the median (Zannad et al., 2000). Moreover, in 
Troponin I positive patients after high-dose chemotherapy, early starting of treatment with 
enalapril prevent the development of late cardiotoxicity (Cardinale et al., 2006b). Obviously, 
blockers of rennin-angiotensin-aldosterone system slow the progression of left ventricular 
dysfunction. 
2.5 Natriuretic peptides  
Natriuretic peptides – brain natriuretic peptide (BNP) and N-terminal probrain natriuretic 
peptide (NT-proBNP), are synthesized in the myocytes in response to high wall stress and 
pressure overload (Yasue et al., 1994). Brain natriuretic peptide causes arterial 
vasodilatation, diuresis, and natriuresis, and reduces the activities of the renin–
angiotensin–aldosterone system and the sympathetic nervous system. Measuring the BNP 
levels not only increases the accuracy of the diagnosis of heart failure in patients 
presenting with dyspnea, when a level of more than 400 pg/ml makes the diagnosis 
likely, but appears to be useful in risk stratification of patients with chronic heart failure 
(Sugiura et al., 2005) and in screening for acute or late cardiotoxic effects associated with 
cancer chemotherapy (Suzuki et al., 1998). Normal plasma concentrations exclude heart 
failure with high negative predictive value of the test. Two studies which have directly 
compared BNP and NT-proBNP, found that the N-terminal prohormone was slightly 
superior to BNP for predicting death or rehospitalization for heart failure because of the 
longer half-life of NT-pro-BNP (Masson et al., 2006). 
The predictive role of NT-proBNP in patients treated with high dose chemotherapy was 
evaluated. In 52 patients after 62 chemotherapy treatments for aggressive malignancies the 
levels of NT-proBNP were measured before the start of high-dose chemotherapy, at the end 
of administration, and 12, 24, 36, and 72 h thereafter (Sandri et al, 2005). Thirty three percent 
of patients had persistently increased NT-proBNP, 36% - only transient increases and 31% 
had no increased values at 72 h. Only patients with persistently increased NT-proBNP 
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developed significant worsening of the left ventricular diastolic indexes from baseline to 12 
months and of the ejection fraction from 62% to 45.6%. In 44 patients BNP-levels at 6-th 
month were significantly increased and in 4 patients they exceeded the upper normal limit 
100 pg/ml, although the patients were asymptomatic (Krastev et al., 2010a).   
2.6 Markers of myocyte injury 
Myocyte injury results from severe ischemia usually, but in heart failure it is also a 
consequence of stresses on the myocardium such as inflammation, oxidative stress, and 
neurohormonal activation. During the past two decades, the myofibrillar proteins — the 
cardiac troponins T and I — have emerged as sensitive and specific markers of myocyte 
injury. Cardiac troponin I was detectable (≥0.04 ng/ml) in approximately half of patients 
with advanced, chronic heart failure without ischemia and after adjustment it remained an 
independent predictor of death (Horwich et al., 2003). Cardiac troponin T levels greater than 
0.02 ng/ml in patients with chronic heart failure were associated with a hazard ratio for 
death of more than 4 (Hudson et al., 2004). The serum levels of troponin T have been shown 
to increase in the early stages of antracyclin therapy and it was associated with diastolic 
dysfunction of the left ventricle (Kilickap et al., 2005). The ability of troponin I to predict 
cardiotoxicity has been tested in 251 women with breast cancer treated with trastuzumab 
(Cardinale et al., 2010c). Positive troponin I was found in 14% of patients and in some of 
them troponin was already positive at baseline, possibly due to myocardial injury caused by 
previous chemotherapy. In the rest of patients the levels of troponin increased during 
therapy with first positive troponin soon after the first trastuzumab cycle. Most patients 
showed only transient positive troponin that normalized within 3 months. In patients with 
positive troponins cardiotoxicity occurrence was observed in period from 1 to 8 months 
after the first detection of positive marker. At multivariate analysis positive troponin was 
the strongest independent predictor of cardiotoxicity with hazard ratio 17.6. In addition to 
predict cardiotoxicity, troponin I predicts lack of cardiac function recovery with positive 
predictive value 65% (lack of ejection fraction recovery in troponin positive patients) and 
negative predicting value 100% (ejection fraction recovery in patients with normal troponin 
I level). Therefore, the authors propose troponin as a criterion standard marker for the 
assessment of cardiac risk of both old and new antineoplastic treatments (Cardinale et 
al., 2010a). 
Other marker is creatine kinase MB fraction (CK-MB) which also circulates in stable patients 
with severe heart failure and is an accurate predictor of death or hospitalization for heart 
failure (Sugiura et al., 2005). During preparative regimen and hematopoietic cell 
transplantation in nineteen patients with acute leukemia, CK-MB mass and troponin T 
concentrations stayed negative, which mean that there was no detectable damage of 
cardiomyocyte structure. At the same time persistent N-terminal pro–brain natriuretic 
peptide elevations were registered, indicated significant cardiotoxicity with risk for 
development of heart failure (Horacek et al., 2007). In 47 adult acute leukemia patients after 
first chemotherapy the levels of Troponin I became elevated (above 0.40 μg/L) in 2 (8.3%) 
patients after first and last chemotherapy with anthracyclines. Both patients with Troponon 
I positivity had elevated glycoprotein phosphorylase. The CK-MB mass stayed in normal 
limits (Horacek et al., 2010). 
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2.7 Heat shock proteins 
Heat shock proteins (HSP) are present in cells in normal conditions but are expressed at 
high levels in high temperature exposition or other stress. HSP27, 70, 90 and 110 increase to 
become the dominantly expressed proteins after stress (Hickey & Weber, 1982, as cited by 
Ciocca & Calderwood, 2005). Heat shock proteins become overexpressed in cancer by 
multiple mechanisms and they are effective biomarkers for carcinogenesis in some tissues 
and signal the degree of differentiation and aggressiveness of certain cancers. The levels of 
HSP and anti-HSP antibodies in the serum of cancer patients are useful in tumor diagnosis. 
Moreover, some HSP are implicated with the prognosis of specific cancers and may also 
predict the response to some anticancer treatments which was summarized in review by 
Ciocca et al. (Ciocca & Calderwood, 2005).  
Implication of HSP in tumor progression and response to therapy has led to its targeting in 
therapy by two main strategies: pharmacological modification of HSP expression or 
molecular chaperon activity, and use of HSPs as adjuvants to present tumor antigens to the 
immune system. Furthermore, it was established that some heat shock proteins have been 
increased by doxorubicin treatment. In vivo rat model the levels of HSP90, known ErbB2 
(epidermal growth factor receptor-2) protein stabilizer and chaperon, are increased by 
treatment with doxorubicin, with revealed binding of HSP90 to ErbB2. Registered in vivo 
increases in HSP90 and ErbB2 cardiac proteins occur even before cardiac dysfunction is 
detected by echocardiography. If a similar relationships occurs in humans this change could 
potentially be used to predict which patients receiving anti-ErbB2 treatment are at risk for 
developing cardiac symptoms. After treatment with HSP90 inhibitor, isolated 
cardiomyocites are more susceptible to doxorubicin, suggesting the protective role of HSP90 
during doxorubicin treatment (Gabrielson et al., 2007). Chronic cyclosporine A treatment 
also induces in vivo HSP90 expression in the heart and is associated with modulation of 
protective endothelial nitric oxide synthase signaling (Rezzani et al., 2003). HSP 70 protects 
the heart from hypoxia or reoxygenation and postinfarction stresses in the heart (Iwaki et 
al., 1993; Marber et al., 1995). The results about HSP70 dynamic during chemotherapy are 
contradictive possibly due to the multitude of roles of HSP70s (Kampinga et al., 2010). In 
animal models the short term cardiotoxicity of dideoxycytidine causes multiple complex 
reactions and depression of HSP 70 levels (Skuta et al., 1999; Šimončiková et al., 2008). 
The new biomarkers which are under investigation are chromogranin A (polypeptide 
hormone produced by the myocardium), galectin-3 (a protein produced by activated 
macrophages) and osteoprotegerin (a member of the tumor necrosis factor receptor 
superfamily) (Braunwald, 2008). 
A multimarker approach is proved to be useful in improving the prognostic significance and 
early detection of development of heart failure. The combination of four biomarkers 
troponin I, NT-pro-BNP, C-reactive protein, and cystatin C, improved risk stratification for 
death from cardiovascular causes among elderly men beyond that of the model based on 
established risk factors (Zethelius et al., 2008). 
The new methods, as the evaluation of proteins using mass spectrometric analysis coupled 
with high-pressure liquid chromatography, is likely to yield totally new classes of 
biomarkers for development of heart failure (Arab et al., 2006). Large platforms that would 
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facilitate the study of hundreds of proteins are likely to become available, which may 
provide a greatly expanded approach to the early detection of ventricular dysfunction, 
elucidating its pathogenesis and making it possible to monitor the therapy. 
3. Echocardiography 
Imaging techniques are conventionally applied in monitoring of chemotherapy-related 
cardiotoxicity to determine left ventricular ejection fraction, on whose drops the definition 
of cardiotoxicity is based. Endomyocardial biopsy has been accepted as the “gold standart” 
test for the evaluation of antracycline-induced cardiomyopathy (Friedman et al., 1978). 
However, the biopsy is an invasive technique with associated risk, which makes it a less 
acceptable method for monitoring the occurrence of cardiotoxicity.   
3.1 Conventional echocardiography 
3.1.1 Current recommendations for monitoring cardiac function by ejection fraction 
and pulsed-wave Doppler echocardiography 
Echocardiography has become the dominant cardiac imaging technique due to its 
portability and versatility. Two-dimensional (2D) echocardiography is currently the first-
line imaging modality for assessing global and regional function. 2D echocardiography 
offers the opportunity to measure end-diastolic and end-systolic volumes (EDV, ESV), and 
thereby to calculate left ventricular (LV) ejection fraction ¹. 
  Ejection fraction = (EDV – ESV)/EDV (1) 
According to European Society for Medical Oncology (ESMO) clinical practice guidelines, 
baseline assessment and periodic monitoring of cardiac function with Doppler 
echocardiography is suggested (Bovelli et al., 2010):  
Baseline assessment of left ventricular systolic and diastolic function is recommended before 
treatment with monoclonal antibodies [III, A] or antracyclines and their derivates in patients 
aged above 60 years, or with cardiovascular risk factors, or previous treatment with 5-
hydroxytryptamine-2B agonists, or documented cardiopathy or previous thoracic 
radiotherapy [III, A].  
In all patients evaluation of ejection fraction is recommended after administration of half the 
planned dose of anthracycline, or after administration of cumulative dose of doxorubicin 
300 mg/m², epirubicin 450 mg/m² or mitoxantrone 60 mg/m² [III, A] or after administration 
of a cumulative dose of doxorubicin of 240 mg/m² or epirubicin 360 mg/m² in patients 
aging under 15 years or above 60 years [III, B].  
Echocardiography should be repeated before every next administration of anthracycline [III, 
A], after 3, 6, and 12 months from the end of therapy with anthracycline [III, B].  
During echocardiography patterns of PW-Doppler of left ventricular in-flow tract and 
pulsed Tissue Doppler Imaging (TDI) of mitral annulus should be evaluated to detect initial 
signs of left ventricular dysfunction that may occur before reduction of ejection fraction. For 
patients receiving monoclonal antibodies, especially if previously treated with 
anthracycline, periodic monitoring every 12 weeks is also suggested [III, A].  
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Assessment of cardiac function is recommended 4 and 10 years after anthracycline therapy 
in patients who were treated at <15 years of age [III, B], or at age >15 years but with 
cumulative dose of doxorubicin of >240 mg/m² or epirubicin >360 mg/m² [III, B].  
Reassessment or discontinuation of therapy with further frequent clinical and 
echocardiographic checks are needed in cases with ejection fraction reduction of ≥20% from 
baseline despite normal function or ejection fraction decline <50%. Mandatory these 
patients, even asymptomatic, should be aggressively medically treated with ACE inhibitors 
and ǃ-blockers.  
According to the guidelines, biomarkers are not included as routine screening 
measurements because their predictive role for cardiotoxicity is not well defined yet. 
Despite all, a persistent increases in cardiac troponin I and BNP levels seem to identify high 
risk patients for cardiotoxicity but this approach is costly and controversial. Using these 
methods patients who need further cardiac assessment may be identified [III, C]. Baseline 
assessment of biomarker concentrations is required and periodic measurements during 
therapy – at the end of therapy administration, after 12, 24, 36, 72 h and 1 month later for 
troponin I, and at the end of medical infusion and after 72 h for BNP. 
The American Society of Echocardiography together with the European Association of 
Echocardiography has updated the recommendations for quantifying cardiac chambers. To 
perform adequate chamber quantification several main requirements should be fulfilled: to 
achieve minimal translational motion of the image, to maximize image resolution, to avoid 
apical foreshortening and maximize endocardial border (Lang et al., 2006). The most 
commonly used for volume measurements is the biplane method of discs (modified 
Simpson’s rule,) and is the currently recommended method of choice. The principle of this 
method is that the total left ventricular volume is calculated from the summation of a stack 
of elliptical discs. The height of each disc is calculated as a fraction of the left ventricular 
long axis based on the longer of the two lengths from the two- and four-chamber views. 
Normal values of left ventricular ejection fraction are ≥55% for both genders (Lang et al., 
2006). The alternative method to calculate volumes when apical endocardial definition is not 
possible is the area-length method where the left ventricle is assumed to be bullet-shaped. 
However, the accuracy of measured left ventricular volumes and ejection fraction depends 
on the expertise of the reader, resulting in large intra- and interobserver variability, and are 
preload-dependent parameters. If a transthoracic window yield unacceptable cardiac 
images because of local surgery or radiation-related changes, an alternative imaging 
modality like radionuclide scanning should be considered (Sengupta et al., 2008). Moreover, 
ejection fraction is not a very sensitive parameter in detecting early alterations in myocardial 
function as they occur in early cardiotoxicity (Schmitt et al., 1995).  
It was established that cardiotoxocity lead to diastolic dysfunction of the left ventricle which 
can be registered with Doppler echocardiography before systolic function occurs (Schmitt et 
al., 1995). The impairement was not lineary related to the cumulative dose of antracyclines, but 
may persist years after treatment with antracyclines (Bu’lock et al., 1995; Hausdorf et al., 1988). 
Conventional Doppler echocardiography with measurements of the velocities of mitral inflow 
(early peak E wave and late peak A wave), deceleration time of early filling and isovolumic 
relaxation time, characterizes the pattern of left ventricular filling (fig. 1 and fig. 2) but is not 
sufficient to differentiate pseudonormal from normal filling because of preload dependence.   
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Fig. 1. Pulsed-wave Doppler of mitral filling. E-wave – early diastolic filling, A-wave – late 
diastolic filling, DT – deceleration time of early mitral filling. 
 
Fig. 2. Isovolumic relaxation time, measured from aortic valve closure to onset of mitral 
filling.  
An algorithm for monitoring cardiac function during trastuzumab therapy is proposed 
(Sengupta et al., 2008). During chemotherapy, if new diastolic dysfunction, independently of 
ejection fraction and clinical symptoms manifestation, is detected, patients should be 
reassessed for risk-benefit of cancer treatment. Heart failure therapy should be started and 
echocardiography performed every 1 week. If heart failure is presented and worsens, 
chemotherapy discontinuation should be considered. If symptoms reverse and left 
ventricular function stabilizes, chemotherapy may be reinstituted. Echocardiographic 
evaluation of ejection fraction and diastolic function continues once every 8 week.  
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3.1.2 Additional echocardiographic methods for early detection of cardiac 
dysfunction 
3.1.2.1 Tei-index  
Tei-index is a combined index for estimation of systolic and diastolic left venrtricular 
function, calculated from the ratio of the difference between time interval from the end to 
the start of transmitral flow (a), and the left ventricular ejection time (b) to the duration of 
ejection time b ² (Tei et al., 1995).  
 Tei-index = (a – b)/b  (2) 
The interval (a) includes the isovolumic contraction time, ejection time and the isovolumic 
relaxation time, and is derived by pulsed-wave Doppler echocardiography with sample 
volume at the tips of the mitral valve leaflets in the 4-apical chamber view (fig. 3). The time 
interval (b) are derived with sample volume in the left ventricular outflow tract from 5-
chamber view (fig. 4). Tei-index may also be expressed as ³: 
 Tei-index = (IVCT + IVRT)/ET   (3) 
IVCT – isovolumic contraction time, IVRT – isovelocity relaxation time, ET – ejection time 
 
Fig. 3. Measurement of interval (a) which includes the isovolumic contraction time, ejection 
time and the isovolumic relaxation time. The spectrogram is registered with PW-Doppler at 
the tips of mitral valve leaflets from apical 4-chamber view.  
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Fig. 4. Measurement of interval (b) which represents the ejection time. The spectrogram is 
registered with PW-Doppler in the left ventricular outflow tract from apical 5-chamber view. 
Calculation of Tei-index is easily obtained and has been proven to be a reliable method for 
evaluation of left ventricular systolic and diastolic performance, because of its load, heart 
rate and age independence, although it is not applicable in patients with rhythm and 
conduction disorders. It appears to be promising parameter for evaluation of myocardial 
dysfunction in large number of diseases but future studies are needed to confirm its 
prognostic power (Lakoumentas et al., 2005).   
According to the results from serial echocardiographic examination of 23 patients on 
anthracycline treatment, the Tei-index is a more sensitive indicator of early cardiotoxicity 
than left ventricular ejection fraction regardless of its value before treatment (Senju et al., 
2007). An additional anthracycline dose significantly correlated with a change in Tei-index, 
in contrast to ejection fraction.  
In 61 cancer patients on chemotherapy, the left ventricular Tie index was significantly 
increased from 0.33 at baseline to 0.44 at 6-th month from chemotherapy, which confirm 
early changes in cardiac function, undetectable by traditional echocardiography (Krastev et 
al., 2010c). Moreover, Tei-index calculated for right ventricle was increased also.       
In 67 consecutive patients on doxorubicin-containing chemotherapy, 26% of patients 
developed cardiotoxicity (Belham et al., 2007). The Tei-index detected declines in left 
ventricular function earlier in the course of anthracycline treatment and to a greater 
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significance than others standard echocardiographic measurements but did not predict 
functional cardiotoxicity.  
Other authors did not find Tei-index to detect early adriamycin cardiotoxicity in adults in 
echocardiographic examination performed at baseline, at an-intermediary cycle and at the 
end of chemotherapy (Rohde et al., 2007). The comparison of its predictive value has been 
done with left ventricular ejection fraction measured by radionuclide ventriculography.  
3.1.2.2 Color-M-mode flow propagation velocity      
Flow propagation velocity Vp, measured with color M-mode Doppler echocardiography as 
a slope of the first color-aliasing from mitral annulus to 4 cm into left ventricular cavity (fig. 
5), is a relatively preload and heart rate independent parameter. It has been shown that Vp 
<45 cm/s to be robust predictor of high left ventricular pressures and cardiovascular 
mortality (Garcia et al., 2000). Moreover, the ratio of E-wave mitral velocity/propagation 
velocity (E/Vp) ≥ 1.5 predicts a left ventricular end-diastolic pressure >15 mmHg and 
differentiates sufficiently pseudonormal from normal left ventricular filling (Garcia et al., 
1997). It has been shown that E/Vp ratio to have prognostic value in postmyocardial 
infarction patients (Moller et al, 2000; Kinova et al, 2004). This method has been validated in 
a heterogeneous group of pediatric patients by comparing the flow propagation velocity Vp 
and septal mitral annular myocardial velocity with simultaneously obtained invasive 
indices of diastolic function (Border et al., 2003). Propagation velocity correlated 
significantly with the time constant of isovolumic relaxation τ (r= -0.56, p=0.01) and with 
peak negative dp/dt (r=0.5, p<0.03), and septal mitral annular myocardial velocity – with 
the time constant of isovolumic relaxation τ (r= -0.58, p=0.01). The E/Vp ratio correlated 
significantly with left ventricular end-diastolic pressure (r=0.71, p <0.001).      
 
Fig. 5. Color M-mode Doppler flow velocity propagation Vp, measured as the first color 
aliasing from mitral annulus to 4 cm into left ventricular cavity from 4-chamber apical view. 
3.2 Tissue Doppler echocardiography 
Tissue Doppler imaging (TDI) uses Doppler principles to measure the velocities of 
myocardial motion which are lower and have higher amplitude than the velocities of blood 
flow. Myocardial velocities are measured only in direction of the ultrasound beam and 
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reflected the absolute tissue motion but with impossibility to discriminate passive from 
active motion. This is the reason for inability of TDI-velocities to differentiate translation or 
tethering motion from myofiber shortening and lengthening. Tissue Doppler Imaging can be 
performed in pulsed-wave and color modes. 
3.2.1 Pulsed-wave tissue Doppler imaging 
In pulsed-wave (PW) Tissue Doppler Imaging (TDI) the Doppler signal from one sample 
region is collected. The spectrogram is represented with Doppler frequency on the vertical 
axis and time on the horizontal axis and it consists of peak systolic myocardial velocity (S-
velocity) and early and late diastolic velocities (E’ and A’ respectively), fig. 6. In apical views 
PW-TDI measures the long-axis ventricular motion well because the longitudinally oriented 
endocardial fibers are parallel to the ultrasound beam. The sample volume is placed in the 
basal myocardial segments adjacent to the annulus and thus PW-TDI has high temporal 
resolution but does not allow simultaneous analysis of multiple myocardial segments.   
 
Fig. 6. Pulsed Tissue Doppler of the medial mitral annulus. S – systolic velocity above the 
baseline as a result of annular movement toward the apex, E’m – early diastolic velocity 
below the baseline due to annular movement away from the apex, A’m – late diastolic 
velocity, at the time of atrial contraction. 
A heterogeneous pattern of systolic and diastolic myocardial velocities was observed 
between individual wall segments and between basal and mid segments of each myocardial 
wall (Galiuto et al., 1998). The velocities are lower in the septum, with higher basal to 
midwall difference. This heterogeneity should be taken into account in clinical application.  
Systolic velocity correlates with peak dp/dt of the left ventricular pressure curve and may 
be useful for noninvasive evaluation of global left ventricular systolic function (Yamada et 
al., 1998). Moreover, TDI of the mitral annulus is an established method for assessment of 
the global diastolic function due to the moving mitral annulus and relatively stationary apex 
throughout the cardiac cycle. The ratio of early mitral velocity E/early mitral annular 
www.intechopen.com
 
Early Detection and Prediction of Cardiotoxicity – Biomarker and Echocardiographic Evaluation 167 
diastolic velocity E’ (E/E’) correlates closely with LV filling pressures (Nagueh et al., 1997; 
Sohn et al., 1997). Mitral E-wave depends on left atrial driving pressure, left ventricular 
relaxation and age, and E’ depends mostly on left ventricular relaxation and age. Hence, in 
the ratio E/E’, effects of left ventricular relaxation and age are eliminated and the ratio 
becomes a measure of left atrial driving pressure or LV filling pressure. Early diastolic E’-
velocity can be conceptualized as the amount of blood entering the LV during early filling, 
whereas mitral E-wave represents the gradient necessary to make this blood enter the left 
ventricle. When the ratio E/E’ exceeds 15, left ventricular filling pressures are elevated, and 
when the ratio is lower than 8, left ventricular filling pressures are low(Paulus et al., 2007). 
The early and late anthracycline effects in 20 adults were evaluated with conventional 
echocardiography and tissue Doppler imaging. Early after chemotherapy (1-3 months) 
changes in left ventricular diastolic function were observed (Tassan-Mangina et al., 2006). The 
mitral E peak velocity and early diastolic myocardial velocity Em of the basal segments of 
lateral and posterior wall decreased significantly. Changes in systolic function with lower 
ejection fraction and systolic myocardial velocities occurred later (3.5 ± 0.6 years) together with 
even more pronounced diastolic changes with decline in late diastolic velocities Am of the 
lateral and posterior wall and early and late diastolic mitral annular velocities. Moreover, a 
short isovolumic relaxation time <80 ms, measured at the mitral annulus level early after 
chemotherapy, predicted with accuracy a late decline of LV ejection fraction below 50%.  
In patients with breast cancer cardiac function has been monitored using Tissue Doppler 
imaging which is found to be more sensitive than standard Doppler for assessment of left 
ventricular diastolic function and 2-dimensional echocardiography for systolic function (Di 
Lisi et al., 2011). These results show that TDI should be integrate in echocardiographic 
examination in monitoring chemotherapy-related cardiotoxicity.   
The applicability of the conventional and tissue Doppler echocardiography for detection of 
late or subclinical cardiotoxicity, following anthracycline chemotherapy was compared in 
forty women (Nagi et al., 2008). After one year diastolic left ventricular function was 
impaired in 97.5% of patients, and in 25% of them diastolic dysfunction could only be 
detected with TDI. At the end of the study the rate of undetectable diastolic dysfunction, 
registered with conventional E/A ratio, rose to 32.5% and TDI was the method for 
identifying these patients.  
In 61 cancer patients treated with cytostatics with known cardiotoxic effects no changes in 
conventional echocardiographic parameters of systolic and diastolic function were 
observed. However, at 6-th month systolic velocity of lateral mitral annulus Sl and all 
medial and lateral annular diastolic velocities (E’m, A’m, E’l, A’l) were significantly reduced 
(Krastev et al., 2010c). Asymptomatic diastolic dysfunction was developed despite of normal 
ejection fraction during and after chemotherapy (Krastev et al., 2010b).      
Serial evaluation of cardiac function in 37 breast cancer patients revealed progressive decrease 
in systolic velocity and early diastolic velocity of medial mitral annulus, and early diastolic 
velocities of inferior and anterior mitral annulus (Tanindi et al., 2011). Pulsed-wave TDI is able 
to detect even subtle changes in right ventricular function during cancer therapy. Systolic and 
early diastolic velocity of lateral tricuspid annulus showed significant reduction from baseline 
to the day after the completion of the first cure, and then to the day after the completion of two 
cures. Late diastolic velocity decreased later after the second cure of chemotherapy. 
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Based on the results for possibility of TDI to identify early diastolic changes in left 
ventricular function in patients on chemotherapy, a randomized clinical trial the Liposomal 
doxorubicin-investigational chemotherapy-Tissue Doppler imaging Evaluation (LITE) to 
compare the safety of lisosomal doxorubicin vs. standard epirubicin in terms of clinical and 
subclinical cardiotoxicity, has been started (Lorionte et al., 2009). The primary end-point will 
be the comparison of changes from baseline to 12-month follow-up of left ventricular 
systolic function TDI-parameters and the co-primary end-point will be based on changes in 
TDI-diastolic parameters.  
3.2.2 Color tissue Doppler imaging 
Color TDI overcomes the limitations of PW-TDI for performing simultaneous analysis of 
different myocardial segments. It represents color-coded myocardial velocities of multiple 
segments at the same time during the cardiac cycle, superimposed on gray-scale 2-
dimensional or M-mode images, in a single view. This improves the spatial resolution. Off-
line analysis allows derivation of time-velocity plots (fig. 7). Velocities measured off-line 
represent regional mean velocity and are lower than peak velocity obtained with PW-TDI. 
The reason is that Doppler signal is collected for each depth and each ultrasound beam 
which limits the ability to calculate full-signal spectra for each position of the image. 
 
Fig. 7. Tissue Doppler Imaging for assessment of regional myocardial velocities. Apical 4-
chamber view with regional analysis of the septal and lateral walls. Region of interest 
include the basal segments and systolic and diastolic velocities in the averaged cardiac cycle 
are presented as color M-mode imaging and curves over time. 
3.2.3 Strain rate imaging by tissue Doppler  
Recently, strain rate imaging, using color-coded tissue Doppler imaging, have emerged as a 
quantitative technique to estimate myocardial function and contractility (Hashimoto et al., 
2003). This method uses Doppler measurements of the myocardium to extract parameters 
such as deformation, strain rate (fig. 8) and strain (fig. 9).   
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Fig. 8. Color M-mode longitudinal strain rate image and strain rate waveforms obtained 
from the same region of interest as the velocity curves - basal septal and lateral walls from 4-
chamber apical view. 
 
Fig. 9. Color M-mode longitudinal strain image and strain waveforms obtained from the 
same region of interest as the velocity curves - basal septal and lateral walls from 4-chamber 
apical view. 
TDI-Strain rate provides differentiation of true contractility from passive myocardial motion 
by accounting relative changes in tissue velocity. Left ventricular function can be assessed in 
one dimension by the analysis of myocardial wall velocity, or by the analysis of wall 
deformation of a myocardial segment (strain rate) and deformation over time (strain). These 
parameters can be measured with sufficient spatial and very good temporal resolution. 
Using TDI-based Strain rate imaging, derivation of longitudinal strain rate and strain in 
apical views, and radial strain rate and strain in short axis views is possible. So far, several 
diseases with subtle impairment of left ventricular function have already been evaluated by 
Strain rate Imaging (SRI), including cardiomyopaties, hypertensive heart disease, ischemic 
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heart disease and proved to be more sensitive than conventional measurements (Abraham 
et al., 2007).  
In a population of children treated with anthracyclines myocardial deformation parameters 
had already changed, while conventional echocardiography did not show any decline in left 
ventricular ejection fraction or fractional shortening after the first two cycles of treatment 
(Ganame et al., 2007a). Regional left ventricular longitudinal and radial systolic strain and 
strain rate were reduced within 2 h after the first dose of anthracyclines. 
In 56 late survivors of childhood cancer, previously treated with anthracyclines at 
supposedly safe doses lower than 300 mg/m², both radial and longitudinal myocardial 
strain was reduced by 15% in patients compared to controls, while ejection fraction 
remained within normal limits at a median of 5.2 years after the completion of therapy 
(Ganame et al., 2007b). 
The feasibility and sensitivity of Doppler-based strain rate imaging in detection of cardiac 
effects of pegylated liposomal doxorubicin have been tested in 16 women with breast cancer 
at baseline and 6 cycles of treatment (Jurcut et al., 2008a). Longitudinal and radial strain and 
strain rate were significantly reduced after 6 cycles. Changes in radial function appeared 
earlier and were more pronounced then longitudinal function.  
The angle-dependence of tissue Doppler-based velocities and strain is the main limitation of 
the method and this makes the measurements of apical segmental velocities and strain 
difficult. The angle dependency is the reason for inability to analyse anything than 
movement in longitudinal direction. The inability of TDI-velocities to reflect the motion 
caused by tethering to adjacent segments is overcome through derivation of strain rate and 
strain, but spatial resolution is impaired by imaging at high temporal resolution. Higher 
spatial resolution is achieved by using of a narrow imaging sector and lower depth but 
decreases the lateral resolution (Marwick et al., 2006). These limitations on lateral resolution 
significantly limit the ability of this technique to assess longitudinal subendocardial and 
subepicardial deformation.       
3.3 Two-dimensional speckle tracking echocardiography 
The real power of speckle analysis is the ability to examine several components or planes 
(i.e. radial, longitudinal and circumferential) in a single data set (Goffinet et al., 2007; 
Gorcsan et al., 2011). By analyzing speckle motion each speckle can be identified and tracked 
by calculating frame to frame changes throughout the cardiac cycle. Speckle tracking 
echocardiography (STE) offers the opportunity to assess myocardial tissue velocity, strain 
and strain rate independently of cardiac translation and beam angle. It requires acquiring at 
least two cardiac cycles for further offline processing and interpretation. Deformation 
parameters are derived for each left ventricular segment and thus allow regional function 
assessment. Global circumferential, radial and longitudinal strain is calculated from the 
mean of all cardiac segments (fig. 10, 11, 12). 
Myocardial strain quantification by speckle tracking echocardiography has been well 
validated, using sonomicrometry and tagged cardiac magnetic resonance as reference 
methods (Amundsen et al., 2006).  
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Fig. 10. 2D-speckle tracking analysis of circumferential strain from parasternal short axis 
view at the level of papillary muscles. 
 
Fig. 11. 2D-speckle tracking analysis of regional and global radial strain from parasternal 
short axis view at the level of papillary muscles. 
 
Fig. 12. 2D-speckle tracking analysis of regional and global longitudinal strain from apical 4-
chamber view. 
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Due to the orientation of left ventricular muscle fibers, varying across the left ventricular 
wall, the shortening of obliquely oriented fibers generates a wringing motion responsible for 
left ventricular torsion. During the cardiac cycle, a systolic twist and an early diastolic 
untwist are generated by opposite basal and apical rotations. Twist or torsion (twist/left 
ventricular length) plays an important role in ejection and in the storage of potential energy 
at end-systole, the release of this energy as elastic recoil during early diastole assists 
ventricular suction. Since left ventricular rotation is sensitive to changes in function it is, 
therefore, of obvious clinical interest to assess left ventricular torsion non-invasively.  
Until recently, tagged cardiac magnetic resonance was the only method capable of assessing 
left venricular torsion non-invasively. Speckle tracking echocardiography has the 
opportunity to assess torsional deformation of the left ventricle (Notomi et al., 2005).With 
the advent of speckle tracking echocardiography, left ventricular torsional deformation can 
be assessed, thus permitting a broader use of this new functional approach. The tissue 
motion quantification software allows the assessment of rotation in subendocardial, midwall 
and subepicardial layers at basal and apical levels (fig. 13 and fig. 14) and thus calculating 
torsion and untwisting. 
Myocardial deformation parameters are superior to conventional measures for detection of 
early subtle alterations in left ventricular function. In 35 female patients treated with 
trastuzumab, ejection fraction with 2D- and 3D-echocardiography and strain and strain rate 
with TDI and 2D speckle tracking echocardiography, were measured every 3 months 
between baseline and 12 months. During the period no overall changes in 2D and 3D 
ejection fraction, myocardial E-velocity and strain were observed. However, significant 
reduction in TDI strain rate, 2D longitudinal strain rate and 2D radial strain rate were 
registered. Three out of 18 patients with reduced longitudinal strain rate had a reduction in 
ejection fraction ≥10% and another 2 developed a reduction over 20 months follow-up (Hare 
et al., 2009). 
 
Fig. 13. Rotation by speckle tracking echocardiography.The curves represents rotation in 
subendocardial, mural and subepicardial layers at the basal left ventricular level from 
parasternal short axis view. 
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Fig. 14. Rotation by speckle tracking echocardiography. The curves represents rotation in 
subendocardial, mural and subepicardial layers at the apical left ventricular level from 
parasternal short axis view. 
The data about the possibility of 2D speckle tracking echocardiography to detect early 
changes in cardiac function during chemotherapy is limited nowadays. However, the results 
of the currently recruiting participants study “Early detection of anthracycline cardiotoxicity 
by echocardiographic analysis of myocardial deformation in 2D strain – CA2D” for analysis 
of myocardial deformation in patients with leukemia, is expected to determine the reliability 
and reproducibility of this method for diagnosis of cardiotoxicty (University Hospital, 
Bordeaux, 2011). 
3.4 Three-dimensional echocardiography 
The interpretation of echocardiographic images requires a complex mental integration of 
multiple image planes for a true understanding of anatomic and pathologic structures. The 
representation of images in a 3-dimensional format more closely resembles reality and could 
therefore enhance image interpretation (Hung et al., 2007). Newer developments use a 
transthoracic probe technology with volumetric scanning capabilities, which allows 
simultaneous acquisition of an entire 3D-data set.  
3D-reconstructions have also been applied to the color Doppler information allowing a three 
dimensional representation of jets superimposed on the 3D-grayscale image. Three-
dimensional transthoracic imaging can be performed with mechanical steering devices, 
which are attached to standard transducers. These devices steer the transducer motion 
causing incremental changes in the scan plane either by rotating, shifting or fanning the 
probe. The advantage of this technique is that freely definable image planes can be chosen 
allowing for more flexibility. This method is capable to increase the reproducibility of 
measured left ventricular ejection fraction as well as is suitable for valve pathology 
assessment. 
Volumetric real-time echocardiography is a recently developed technique based on the 
design of an ultrasound transducer with a matrix array that instantaneously acquires the 
image and allows instant (real-time) acquisition of a complete 3-dimensional data set 
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without complex post-processing (Kisslo et al., as cited by Binder, 2002). 3D-
echocardiography is reliable, although image quality can be a problem in some patients. 
Magnetic resonance imaging is suitable in these patients. 
The use of new echocardiographic methods requires additional time to the conventional 
echo study and further studies are needed to determine the most feasible parameters and 
their cut-off values, which can be used for prediction of deterioration of global ventricular 
function with heart failure.  
4. Disadvantages of using biomarkers and echocardiography for early 
cardiotoxicity detection  
Most studies have investigated separately echocardiographic variables and biomarkers to 
identify patients at risk for later cardiotoxicity. There is little information about the ability of 
both techniques in the same cohort of patients. At present, it is not clear enough which of 
the investigated parametes – biomarkers or echocardiographic may detect earlier subtle 
changes in cardiac function.  
Measurement of troponins and natriuretic peptides is easy of access in clinical practice. 
Elevation of troponin may be reliable in prediction of cardiotoxicity but different 
laboratories use different assays and cut-off values. Elevated troponin I (positive) was 
defined as any value exceeding the cut-off level of 0.4 ng/ml (Krastev et al., 2010) or 0.08 
ng/ml (Cardinale et al., 2010) in different studies. For troponin T was used 0.1 ng/ml as the 
upper limit of the normal range and in this study elevation of troponon T levels were 
associated with left ventricular diastolic dysfunction, registered through prolongation of 
post-treatment isovolumic relaxation time (Kilickap et al., 2005). For BNP and pro-BNP are 
valid the same conditions in measurement.  
Myocardial deformational imaging seems to have increased sensitivity compared to 
conventional echocardiography in detection of early cardiac changes. This may be related to 
the possibility of regional character of the cardiotoxicity at the beginning when global 
function, measured by ejection fraction is preserved. Several questions remain opened. It is 
not clear enough if regional dysfunction, diagnosed by strain, is clinically essential. If it is 
important - what are the cut-off values of these parameters for prediction of cardiotoxicity. 
Larger studies with long-term follow-up of children and adults after chemotherapy, with 
multivariable approach, are needed to clarify these issues.      
5. Conclusions 
Biomarkers as Troponin I and natriuretic peptides, measured before starting chemotherapy 
and after each cure, may be used to predict cardiotoxicity. Large prospective and 
multicenter studies are needed to define the potential role of new circulating biomarkers in 
the assessment of chemotherapy-related cardiotoxicity.  
In addition to conventional 2D- and Doppler echocardiography, pulsed-wave tissue 
Doppler echocardiography is a reliable, simple and reproducible method, which may be 
included in serial echocardiographic evaluation routinely in all patients during 
chemotherapy. Measurement of mitral annular velocities provides information not only for 
left ventricular global diastolic function and filling pressures, but detects subtle changes in 
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systolic function through measurement of systolic velocity. Myocardial deformation 
imaging may be used in selected patients for more detailed regional and global analysis. 
Further studies will establish the role of 2D-strain for prediction of cardiotoxicity. 3D-
echocardiography overcomes the limits of 2D-echocardiography in measuring ejection 
fraction which depends on left ventricular geometry. 
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